



**Schizophrenia
& Psychosis**
Action Alliance

Schizophrenia & Psychosis Action Alliance Joins NIH Public-Private Partnership To Advance Early Interventions for Schizophrenia

Alexandria, VA, April 5, 2021 – The Schizophrenia & Psychosis Action Alliance enthusiastically joins the [Accelerating Medicines Partnership \(AMP\)](#), a unique public-private partnership launched by the National Institute of Health (NIH) aimed at meeting the urgent need for identifying new, effective therapeutic interventions for people at risk of developing, or those living with, schizophrenia.

AMP Schizophrenia brings together NIH, the Food & Drug Administration, the European Medicines Agency (EMA) and multiple not-for-profit and private organizations to advance promising biological markers that can help identify people at risk of developing schizophrenia as early as possible and develop measures that further define early stages of risk and predict the likelihood of progression to psychosis. This work will allow for early intervention and testing of treatments that may prevent the development or progression of schizophrenia. All data and analyses will be publicly available through the [NIMH Data Archive](#).

“The Schizophrenia & Psychosis Action Alliance is taking meaningful action to transform lives by being a catalyst for new research approaches which can lead to breakthroughs in new treatment options for those living with schizophrenia and psychosis. Since our founding 13 years ago, the pace and progress in biomedical research has been slower than we hoped. Since every day without treatment makes a difference between life and death, we are committed to working within this partnership to help accelerate scientific knowledge, new research approaches and promote public policies which can help save lives,” said Mary Palafox, RN, Board Chair, Schizophrenia & Psychosis Action Alliance.

Over the next five years, the National Institute of Mental Health (NIMH) expects to contribute \$82.5 million towards the AMP partnership. Together the private partner organizations will invest \$17 million through the Foundation for the National Institutes of Health (FNIH), a not-for-profit organization, which manages the project.

###

About Schizophrenia & Psychosis Action Alliance

The Schizophrenia & Psychosis Action Alliance is a global impact organization moving individuals, families and policies forward to improve and save lives by changing the treatment paradigm for all persons affected by schizophrenia-related brain diseases which involve psychosis. Every day without treatment can mean the difference between life and death. We envision a day when the reclassification of schizophrenia as a neurological designation allows every person living with a schizophrenia-related brain disease to receive respect, appropriate treatment, and an opportunity to live a meaningful and satisfying life in a compassionate community free of discrimination. We stand for hope and recovery through promoting peer-based support programs, helping accelerate scientific knowledge, identifying effective treatments, and promoting effective public policies. To learn more information, please visit www.sczaction.org.

Media Contact

Tel: +1 (240) 423-9432

E-mail: info@sczaction.org